Company registration number 10714939 (England and Wales)
LIFECAST BODY SIMULATION LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
LIFECAST BODY SIMULATION LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 11
LIFECAST BODY SIMULATION LIMITED
COMPANY INFORMATION
Directors
Mr T Murray
Mr J Radak
Mr M G Sprott
Company number
10714939
Registered office
Workshop 6 Elstree Studios
Shenley Road
Borehamwood
Hertfordshire
England
WD6 1JG
Auditor
Shaw Wallace
Chartered accountants & statutory auditor
43 Manchester Street
London
W1U 7LP
LIFECAST BODY SIMULATION LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
7
4,454
4,454
Tangible assets
6
40,839
23,199
45,293
27,653
Current assets
Stocks
8
157,270
91,651
Debtors
9
1,430,965
1,290,015
Cash at bank and in hand
86,254
288,404
1,674,489
1,670,070
Creditors: amounts falling due within one year
10
(208,598)
(350,168)
Net current assets
1,465,891
1,319,902
Total assets less current liabilities
1,511,184
1,347,555
Provisions for liabilities
Deferred tax liability
11
10,210
(10,210)
-
Net assets
1,500,974
1,347,555
Capital and reserves
Called up share capital
13
6,000
6,000
Profit and loss reserves
1,494,974
1,341,555
Total equity
1,500,974
1,347,555
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
The financial statements were approved by the board of directors and authorised for issue on 22 July 2025 and are signed on its behalf by:
Mr J Radak
Director
Company registration number 10714939 (England and Wales)
LIFECAST BODY SIMULATION LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 April 2023
6,000
1,099,129
1,105,129
Year ended 31 December 2023:
Profit and total comprehensive income
-
242,426
242,426
Balance at 31 December 2023
6,000
1,341,555
1,347,555
Year ended 31 December 2024:
Profit and total comprehensive income
-
153,419
153,419
Balance at 31 December 2024
6,000
1,494,974
1,500,974
LIFECAST BODY SIMULATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
1
Accounting policies
Company information
Lifecast Body Simulation Limited is a private company limited by shares incorporated in England and Wales. The registered office is Workshop 6 Elstree Studios, Shenley Road, Borehamwood, Hertfordshire, England, WD6 1JG.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:
No cashflow statement has been presented for the company.
Disclosures in respect of financial instruments have not been presented.
No disclosure has been given for the aggregate remuneration of key management personnel.
The financial statements of the company are consolidated in the financial statements of Sydney US Buyer Corp. These consolidated financial statements are available from its registered office, 2929 Walnut Street, Suite 1240, Philadephia, PA 19104, United States.
1.2
Going concern
Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Turnover
Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.
When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.
LIFECAST BODY SIMULATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -
Royalty income is recognised monthly based on the number of items sold.
1.4
Intangible fixed assets other than goodwill
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.
The company does not amortise patents and licenses.
1.5
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Plant and equipment
25% straight line basis
Computers
25% straight line basis
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.6
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
LIFECAST BODY SIMULATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
1.7
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.8
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.9
Financial instruments
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
LIFECAST BODY SIMULATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 6 -
1.10
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.11
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.12
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.13
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.14
Leases
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
LIFECAST BODY SIMULATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
2
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
3
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2024
2023
Number
Number
Administrative staff
1
2
Management staff
1
2
Total
2
4
4
Directors' remuneration
2024
2023
£
£
Remuneration for qualifying services
94,359
5
Taxation
2024
2023
£
£
Current tax
UK corporation tax on profits for the current period
21,066
27,739
Adjustments in respect of prior periods
(84,874)
Total current tax
(63,808)
27,739
Deferred tax
Origination and reversal of timing differences
10,210
Total tax (credit)/charge
(53,598)
27,739
LIFECAST BODY SIMULATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
5
Taxation
(Continued)
- 8 -
The actual (credit)/charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2024
2023
£
£
Profit before taxation
99,821
270,165
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 25.00%)
24,955
67,541
Tax effect of expenses that are not deductible in determining taxable profit
521
588
Permanent capital allowances in excess of depreciation
(4,410)
(5,375)
Research and development tax credit
(57,135)
Under/(over) provided in prior years
(27,739)
Deferred tax
10,210
Utilisation of tax losses
(35,015)
Taxation (credit)/charge for the year
(53,598)
27,739
6
Tangible fixed assets
Plant and equipment
Computers
Total
£
£
£
Cost
At 1 January 2024
22,730
2,698
25,428
Additions
23,390
4,218
27,608
At 31 December 2024
46,120
6,916
53,036
Depreciation and impairment
At 1 January 2024
1,704
525
2,229
Depreciation charged in the year
8,939
1,029
9,968
At 31 December 2024
10,643
1,554
12,197
Carrying amount
At 31 December 2024
35,477
5,362
40,839
At 31 December 2023
21,026
2,173
23,199
LIFECAST BODY SIMULATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 9 -
7
Intangible fixed assets
Patents, trademarks and licenses
£
Cost
At 1 January 2024 and 31 December 2024
4,454
Amortisation and impairment
At 1 January 2024 and 31 December 2024
Carrying amount
At 31 December 2024
4,454
At 31 December 2023
4,454
8
Stocks
2024
2023
£
£
Raw materials and consumables
15,504
21,854
Work in progress
49,273
26,127
Finished goods and goods for resale
92,493
43,670
157,270
91,651
9
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
220,402
109,351
Corporation tax recoverable
57,135
Other debtors
24,770
116,783
302,307
226,134
2024
2023
Amounts falling due after more than one year:
£
£
Amounts owed by group undertakings
1,128,658
1,063,881
Total debtors
1,430,965
1,290,015
The amount owed by the group undertaking represents a loan provided to immediate parent undertaking 3B Scientific UK Limited. The interest is accrued at 3 months' Euribor base rates plus 6% on the loan amount outstanding.
The loan is repayable in full by 7th July 2029.
LIFECAST BODY SIMULATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 10 -
10
Creditors: amounts falling due within one year
2024
2023
Notes
£
£
Trade creditors
129,111
162,164
Corporation tax
21,066
28,267
Other taxation and social security
4,515
12,695
Deferred income
12
92,555
Other creditors
1,171
Accruals and deferred income
53,906
53,316
208,598
350,168
11
Deferred taxation
The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:
Liabilities
Liabilities
2024
2023
Balances:
£
£
Accelerated capital allowances
10,210
-
2024
Movements in the year:
£
Liability at 1 January 2024
-
Charge to profit or loss
10,210
Liability at 31 December 2024
10,210
The deferred tax liability set out above is expected to reverse within [12 months] and relates to accelerated capital allowances that are expected to mature within the same period.
12
Deferred income
2024
2023
£
£
Other deferred income
-
92,555
13
Share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
6,000
6,000
6,000
6,000
LIFECAST BODY SIMULATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 11 -
14
Audit report information
As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.
The auditor's report is unqualified and includes the following:
Opinion
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
Senior Statutory Auditor:
Hitesh Gadhia
Statutory Auditor:
Shaw Wallace
Date of audit report:
22 July 2025
15
Related party transactions
Transactions with related parties
The company has taken advantage of the exemption by paragraph 33.1(a) of FRS102 Related Party Disclosures not to disclose transactions with group companies which are wholly owned subsidiary of the group.
16
Ultimate controlling party
Lifecast Body Simulation Limited is a wholly owned subsidiary of UK 3B Scientific Limited, a company incorporated in the United Kingdom and registered office is 9 Regent Street, Burnham-On-Sea, Somerset, United Kingdom, TA8 1AX.
UK 3B Scientific Limited is a wholly owned subsidiary of American 3B Scientific LP, a limited partnership incorporated in the United States.
The parent company which draws up consolidated financial statements for the group is Sydney US Buyer Corp. The company address of Sydney US Buyer Corp. is 2929 Walnut Street, Suite 1240, Philadephia, PA 19104, United States.
2024-12-312024-01-01falsefalsefalse22 July 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityMr T MurrayMr J RadakMr M G Sprott107149392024-01-012024-12-3110714939bus:Director12024-01-012024-12-3110714939bus:Director22024-01-012024-12-3110714939bus:Director32024-01-012024-12-31107149392024-12-3110714939core:IntangibleAssetsOtherThanGoodwill2024-12-3110714939core:IntangibleAssetsOtherThanGoodwill2023-12-3110714939core:PatentsTrademarksLicencesConcessionsSimilar2024-12-3110714939core:PatentsTrademarksLicencesConcessionsSimilar2023-12-31107149392023-12-3110714939core:PlantMachinery2024-12-3110714939core:ComputerEquipment2024-12-3110714939core:PlantMachinery2023-12-3110714939core:ComputerEquipment2023-12-3110714939core:ShareCapital2024-12-3110714939core:ShareCapital2023-12-3110714939core:RetainedEarningsAccumulatedLosses2024-12-3110714939core:RetainedEarningsAccumulatedLosses2023-12-3110714939core:ShareCapital2023-03-3110714939core:RetainedEarningsAccumulatedLosses2023-03-3110714939core:ShareCapitalOrdinaryShareClass12024-12-3110714939core:ShareCapitalOrdinaryShareClass12023-12-3110714939core:RetainedEarningsAccumulatedLosses2023-04-012023-12-31107149392023-04-012023-12-3110714939core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3110714939core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3110714939core:PlantMachinery2024-01-012024-12-3110714939core:ComputerEquipment2024-01-012024-12-3110714939core:UKTax2024-01-012024-12-3110714939core:UKTax2023-04-012023-12-311071493912024-01-012024-12-311071493912023-04-012023-12-311071493922024-01-012024-12-311071493922023-04-012023-12-311071493932024-01-012024-12-311071493932023-04-012023-12-3110714939core:PlantMachinery2023-12-3110714939core:ComputerEquipment2023-12-31107149392023-12-3110714939core:PatentsTrademarksLicencesConcessionsSimilar2023-12-3110714939core:CurrentFinancialInstruments2024-12-3110714939core:CurrentFinancialInstruments2023-12-3110714939core:AfterOneYear2024-12-3110714939core:AfterOneYear2023-12-3110714939bus:OrdinaryShareClass12024-01-012024-12-3110714939bus:OrdinaryShareClass12024-12-3110714939bus:OrdinaryShareClass12023-12-3110714939bus:PrivateLimitedCompanyLtd2024-01-012024-12-3110714939bus:FRS1022024-01-012024-12-3110714939bus:Audited2024-01-012024-12-3110714939bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3110714939bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP